Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Metabolites ; 13(3)2023 Mar 14.
Artículo en Inglés | MEDLINE | ID: mdl-36984867

RESUMEN

Type 2 diabetes mellitus (T2DM) is characterized by impaired insulin secretion on a background of insulin resistance (IR). IR and T2DM are associated with atherosclerotic coronary artery disease (CAD). The mechanisms of IR and atherosclerosis are known to share similar genetic and environmental roots. Endothelial dysfunction (ED) detected at the earliest stages of IR might be the origin of atherosclerosis progression. ED influences the secretion of pro-inflammatory cytokines and their encoding genes. The genes and their single nucleotide polymorphisms (SNPs) act as potential genetic markers of IR and atherosclerosis. This review focuses on the link between IR, T2DM, atherosclerosis, CAD, and the potential genetic markers CHI3L1, CD36, LEPR, RETN, IL-18, RBP-4, and RARRES2 genes.

2.
Curr Pharm Des ; 23(25): 3689-3698, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28625137

RESUMEN

BACKGROUND: Chemerin is an adipokine that induces insulin resistance by the mechanism of inflammation in adipose tissue but these are still unclear. A high level of chemerin in humans is considered as a marker of inflammation in insulin resistance and obesity as well as in type 2 diabetes mellitus. Despite the role of chemerin in insulin resistance progression, chemerin as one of the novel adipokines is proposed to be involved in high cancer risk and mortality. AIM: The aim of this paper was to review the role of CMKLR-1 receptor and the potential therapeutic target in the management of chemerin induced type 2 diabetes mellitus and cancer. PATHOPHYSIOLOGY: Increased chemerin secretion activates an inflammatory response. The inflammatory response will increase the oxidative stress in adipose tissue and consequently results in an insulin-resistant state. The occurrence of inflammation, oxidative stress and insulin resistance leads to the progression of cancers. CONCLUSION: Chemerin is one of the markers that may involve in development of both cancer and insulin resistance. Chemokine like receptor- 1 (CMKLR-1) receptor that regulates chemerin levels exhibits a potential therapeutic target for insulin resistance, type 2 diabetes and cancer treatment.


Asunto(s)
Antineoplásicos/administración & dosificación , Diabetes Mellitus Tipo 2/metabolismo , Sistemas de Liberación de Medicamentos/tendencias , Hipoglucemiantes/administración & dosificación , Neoplasias/metabolismo , Receptores de Quimiocina/metabolismo , Animales , Antineoplásicos/metabolismo , Estudios de Casos y Controles , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Manejo de la Enfermedad , Sistemas de Liberación de Medicamentos/métodos , Humanos , Hipoglucemiantes/metabolismo , Resistencia a la Insulina/fisiología , Neoplasias/tratamiento farmacológico , Receptores de Quimiocina/antagonistas & inhibidores
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA